• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Dr. Peter Davies, Applied NeuroSolutions' Founding Scientist, to Be Featured on a National Public Radio Broadcast Panel on Alzheimer's

Posted on: Wednesday, 13 June 2007, 09:05 CDT

Applied NeuroSolutions, Inc. (OTCBB:APNS) (www.appliedneurosolutions.com) a Company focused on the development of an integrated product portfolio for the treatment and diagnosis of Alzheimer's disease (AD), today announced it's long-standing founding scientist, Dr. Peter Davies, a world renowned expert on AD research, is scheduled to be discussing the state of AD research today on National Public Radio. The Diane Rehm Show is based in Washington, DC, and has been on the air for 27 years and reaches more than 1.7 million people. Dr. Davies will be joined on the program by others from the Alzheimer's Association.

The show is scheduled to air from 10:00am to 11:00am Eastern Time and can be accessed via the internet at www.drshow.org. Dr. Davies, the Judith and Burton P. Resnick Professor of Alzheimer's Disease Research at the Albert Einstein College of Medicine, is expected to discuss the current state of AD research, including the theories he has been focused on over his 30 year career. Dr. Davies' novel approach, as well as the tools developed with the scientists at APNS, were key components of the interest of large pharma companies, that ultimately culminated in a collaboration agreement with Eli Lilly and Company (NYSE:LLY) to develop therapeutics to treat Alzheimer's disease.

About Applied NeuroSolutions:

Applied NeuroSolutions, Inc. (OTCBB:APNS) is developing, in collaboration with Eli Lilly and Company, novel therapeutic compounds to treat and diagnostics to detect Alzheimer's disease (AD) based on discoveries originating from the Albert Einstein College of Medicine. Applied NeuroSolutions has discovered biomarkers that the company believes will aid in the development of effective AD treatments. Applied NeuroSolutions has also been working on both a cerebrospinal fluid (CSF) diagnostic test and blood tests to detect AD at a very early stage. The CSF test can already differentiate AD patients from those with other diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect Alzheimer's disease. Alzheimer's disease currently afflicts over 5 million Americans, and the world market for AD therapy is currently estimated to be 30 million patients. For more information, visit www.appliedneurosolutions.com.

This press release contains forward-looking statements about Applied NeuroSolutions. The company wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category